Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Significance: This study suggests, for the first time, Interleukin-37 (IL-37), by suppressing the expression of its target gene, it may increase the expression of tumor suppressor BTG2. Thus, pharmacological formulations encompassing “IL-37 or its activators” can be used to inhibit the progression of human tumors.
Citation: Boominathan, Interleukin-based anti-cancer therapy: Interleukin-37 (IL-37) increases the expression of BTG2 via down regulation of its target gene, 08/March/2015, 17.13, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at firstname.lastname@example.org
Undisclosed information: How IL-37 increases the expression of tumor suppressor BTG2
* Research cooperation